Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, ***e
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the compounds of the present invention have particularly advantageous properties by selectively binding to the 5-HT 2C serotoninergic receptors with respect to the 5-HT 2A receptors.
• This novel property has never been demonstrated for the most closely related compounds of the prior art such as, for example, those described in patents WO 9006927, EP 410,535, EP 539,209 or EP 95666.
• 5-HT serotonin
• 5-HT 2A and 5-HT 2C good indications exist that they are more particularly involved in controlling mood (J. F. W. Deakin, Pharmacol. Biochem. Behav., 29, 819-820, 1988) as well as in the modulation of several physiological functions such as the appetite (G. A. Kennett et at., Eur. J. Pharmacol., 164, 445-454, 1989), sleep (C.
• the compounds described in the present invention bind selectively to the 5-HT 2C receptors with respect to the 5-HT 2A receptors and are antagonists which may thus be used in the treatment of diseases such as anxiety, depression, impulse disorders (such as aggression, B. A. McMillen, Drug. Develop. Persp., 12, 53-62, 1988), schizophrenia, appetite disorders (such as anorexia), cardiovascular diseases, sexual dysfunction (H. H. G. Berendsen et al., Psychopharmacology, 101, 57-61, 1990), cerebral ischemic attacks (F. Granier et al., Acta Psychiatr. Stand., 72, 67-74, 1985; W. D. Dietrich et al., J. Cereb.
• diseases such as anxiety, depression, impulse disorders (such as aggression, B. A. McMillen, Drug. Develop. Persp., 12, 53-62, 1988), schizophrenia, appetite disorders (such as anorexia), cardiovascular diseases, sexual dysfunction (H. H. G. Berendsen
• n 1 or 2
• R 1 represents a hydrogen atom or a linear or branched (C 1 -C 6 ) alkyl group, a benzyl, acetyl, benzoyl, allyl, pyridinecarbonyl or pyridinemethyl group, a pyridineaminocarbonyl group, a linear or branched (C 1 -C 6 ) phthalimidoalkyl group, a linear or branched (C 1 -C 4 ) (thiochroman-8-yloxy)alkyl group, a linear or branched (C 1 -C 4 ) (benzodioxanyloxy)alkyl group or a linear or branched (C 1 -C 6 ) acylaminoalkyl group, (wherein acyl is a benzoyl group, a naphtylcarbonyl group, a thienylcarbonyl group, a linear or branched (C 1 -C 6 ) alkylcarbony
• R 2 , R 3 or R 4 which may be identical or different, represent a hydrogen or halogen atom or a linear or branched (C 1 -C 6 ) alkyl group, a linear or branched (C 1 -C 6 ) alkoxy group, a hydroxyl, acetyl, aminocarbonyl, aminomethyl, cyano, nitro or amino group, a phenyl group (which may or may not be substituted with one or more halogen atoms or hydroxyl groups, linear or branched (C 1 -C 6 ) alkoxy groups, linear or branched (C 1 -C 6 ) alkyl groups or trihalomethyl groups), a furyl group, a pyridinyl group, a thienyl group or a pyrrolyl group, or alternatively, when they are located on adjacent carbons, R 2 and R 3 form, with the carbon atoms which bear them, a furan or phenyl ring,
• acids which may be mentioned, without any limitation, are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid, etc.
• the invention also relates to the process for the preparation of the compounds of formula (I).
• a pyrrolidine of formula (II) is used as starting material, in the form of a pair of enantiomers or a pure enantiomer: ##STR3## in which R 2 , R 3 and R 4 are as defined in formula (I), which compound of formula (II), when it is in the form of a pair of enantiomers, is reacted with lithium aluminum hydride in an inert solvent to give the pyrrolidine of formula (III): ##STR4## in which R 2 , R 3 and R 4 have the same meaning as in formula (I),
• X represents a halogen atom
• R' 1 represents a linear or branched (C 1 -C 6 ) alkyl group, an acetyl, benzoyl, pyridinecarbonyl, pyridinemethyl or 3-pyridineaminocarbonyl group or a linear or branched (C 1 -C 6 ) phthalimidoalkyl group,
• the compounds of formula (IV) may also be obtained, when the pyrrolidine possesses hydrogen atoms in a cis position relative to each other, by performing a cycloaddition according to the process described by K.
• Achiwa et al. (cited above) of a coumarin of formula (VI): ##STR12## in which R 2 , R 3 and R 4 have the same meaning as in formula (I),
• the starting material used is the compound of formula (IX): ##STR15## in which R 2 , R 3 and R 4 are as defined in formula (I), which compound is reacted, according to the method described in Can. J. Chem., 52, 2316, 1974, with methylmagnesium bromide and then with p-toluenesulfonic acid,
• X represents a halogen atom
• R' 1A represents a linear or branched (C 1 -C 6 ) alkyl group, an acetyl, benzoyl, benzyl, pyridinecarbonyl, pyridinemethyl or 3-pyridineaminocarbonyl group or a linear or branched (C 1 -C 6 ) phthalimidoalkyl group,
• R 2 , R 3 and R 4 have the same meaning as in formula (I) and R" 1A represents a linear or branched (C 1 -C 6 ) alkyl group, an acetyl, benzoyl, benzyl, pyridinecarbonyl, pyridinemethyl or 3-pyridineaminocarbonyl group or a linear or branched (C 1 -C 6 ) phthalimidoalkyl group,
• compositions containing, as active principle, at least one compound of formula (I) alone or in combination with one or more inert, non-toxic excipients or vehicles.
• compositions according to the invention there may more particularly be mentioned those which are suitable for oral, parenteral and nasal administration, simple or coated tablets, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, dermal gels, etc.
• the appropriate dosage varies depending on the age and weight of the patient, the nature and severity of the complaint and the route of administration.
• the latter may be an oral, nasal, rectal or parenteral route.
• the unit dosage ranges between 1 and 500 mg for a treatment of 1 to 3 doses taken per 24 hours.
• the expected product is obtained according to the process described by K. Achiwa et al. (Chem. Pharm. Bull., 33(7), 2762-2766, 1985).
• the reaction medium is brought from 30° C. to 55° C. over 75 minutes. 0.75 g of potassium carbonate is then added and the mixture is kept stirring for 15 minutes.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2,6-dimethoxy)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2,5-dimethoxy)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using coumarin as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl cis-(2,6-dimethoxy)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2-methoxy-4-chloro)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using 7-methoxycoumarin as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2,4-dimethoxy)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2,3-dimethoxy)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using 6-chlorocoumarin as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2-methoxy-5-chloro)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using 8-chlorocoumarin as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2-methoxy-3-chloro)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-(2-methoxy-5-bromo)cinnamate as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-3-(2-methoxynaphth-1-yl)acrylate as starting material.
• the expected product is obtained according to the process described in Preparation A, using methyl trans-3-(1-methoxynaphth-1-yl)acrylate as starting material.
• the expected product is obtained according to the process described in Preparation A, using benzo[h]chroman-2-one as starting material.
• the expected product is obtained according to the process described in Preparation A, using benzo[f]chromen-3-one as starting material.
• the expected product is obtained according to the process described in Stage A of Example 1, using methyl [trans-1-benzyl-4-(2,6-dimethoxyphenyl)pyrrolidin-3-yl]carboxylate, described in Preparation B, as starting material.
• the expected product is obtained according to the process described in Stage C of Example 1.
• the expected product is obtained according to the process described in Stage D of Example 1.
• Example 4 To 3.3 mmol of the compound obtained in Example 4, dissolved in 30 ml of chloroform, are successively added 6.6 mmol of triethylamine and then 3.3 mmol of allyl bromide. The reaction medium is maintained at reflux for one hour and then hydrolyzed with 1N sodium hydroxide. After extraction with chloroform, the organic phases are combined, dried and evaporated. The expected product is obtained after purification of the residue by column chromatography on silica, using a dichloromethane/methanol/aqueous ammonia mixture (95/5/0.5) as eluent.
• Stage B trans-2-(2-Aminoethyl)-9-methoxy-1,3,3a,4,9b-pentahydro-(1)-benzopyrano[3,4-c]pyrrole
• Stage C trans-2-[3-(4-Fluorobenzoylamino)ethyl]-9-methoxy-1,3,3a,4,9b-pentahydro-(1)-benzopyrano[3,4-c]pyrrole
• the expected product is obtained according to the process described in Stage A of Example 1, starting with methyl [trans-1-benzyl-4-(2,5-dimethoxyphenyl)pyrrolidin-3-yl]carboxylate described in Preparation C.
• the expected product is obtained according to the process described in Stage C of Example 1, starting with the compound obtained in the above stage.
• the expected product is obtained according to the process described in Stage D of Example 1, starting with the compound obtained in the above stage.
• the expected product is obtained according to the process described in Example 4, starting with the compound obtained in Example 9.
• the expected product is obtained according to the process described in Example 6, starting with the compound described in Example 10. Chromatographic purification is performed using a dichloromethane/methanol mixture (95/5) as eluent, and gives the hydrochloride.
• 125 mmol of cis-2-benzyl-1,3,3a,9b-tetrahydrobenzopyrano[3,4-c]pyrrol-4-one (described in Preparation D) are added to a heterogeneous solution containing 310 mmol of lithium aluminum hydride in 800 ml of THF at 5° C.
• the reaction medium is kept stirring for 3 hours at room temperature and is then cooled to +10° C.
• 120 ml of ethyl alcohol, 120 ml of water and then 40 ml of aqueous 40% sodium hydroxide solution are successively added. After filtration of the salts, the filtrate is washed with saturated sodium bicarbonate solution. The organic phase is dried and, after evaporation, gives the expected product.
• the expected product is obtained according to the process described in Stage C of Example 1, starting with the compound described in the above stage.
• the expected product is obtained according to the process described in Stage D of Example 1, starting with the compound obtained in the above stage.
• the expected product is obtained according to the process described in Example 4, starting with the compound obtained in Example 12.
• the expected product is obtained according to the process described in Stage A of Example 12, starting with methyl [cis-1-benzyl-4-(2,6-dimethoxyphenyl)pyrrolidin-3-yl]carboxylate described in Preparation E.
• the expected product is obtained according to the process described in Stage C of Example 1, starting with the compound described in the above stage.
• the expected product is obtained according to the process described in Stage D of Example 1.
• the expected product is obtained according to the process described in Example 4, starting with the compound described in Example 15.
• the expected product is obtained according to the process described in Example 5, starting with the compound described in Example 16.
• the expected product is obtained according to the process described in Stage A of Example 1, using methyl [trans-1-benzyl-4-(2-methoxy-4-chlorophenyl)pyrrolidin-3-yl]carboxylate, described in Preparation F, as starting material.
• the expected product is obtained according to the process described in Stage B of Example 9, starting with the compound obtained in the above stage.
• the expected product is obtained according to the process described in Stage C of Example 1, starting with the compound obtained in the above stage.
• the expected product is obtained according to the process described in Stage D of Example 3 (using two equivalents of sodium hydride), starting with the compound obtained in the above stage.
• the expected product is obtained according to the process described in Stage A of the Example 1, using the compound described in Preparation H.
• the expected product is obtained according to the process described in Stage B of Example 1, using the compound obtained in the above stage as starting material.
• the expected product is obtained according to the process described in Stage B of Example 21, starting with the compound obtained in the above stage.
• the expected product is obtained according to Stages A, B and C of Example 23, starting with the compound obtained from Preparation I.
• the expected product is obtained according to the process described in Stage A of Example 12, using the compound described in Preparation J as starting material.
• the expected product is obtained according to the process described in Stage B of Example 21, starting with the compound obtained in the above stage.
• the expected product is obtained according to Stages A, B and C of Example 22, starting with the compound obtained from Preparation K.
• the expected product is prepared according to Stage A of Example 12 and then Stage B of Example 21, starting with the compound obtained in Preparation L.
• the expected product is obtained according to Stages A, B and C of Example 1 and then according to Stage D of Example 3, starting with the compound obtained in Preparation M.
• the expected product is obtained according to Stages A, B and C of Example 1 followed by Stage D of Example 3, starting with the compound obtained in Preparation N.
• Example 30 The compound obtained in Example 30 is treated according to the procedure described for Example 6.
• the expected product is obtained according to Stages A, B and C of Example 1 followed by Stage D of Example 3, starting with the compound obtained in Preparation O.
• Example 32 The product obtained in Example 32 is treated according to the procedure of Example 30.
• the expected product is obtained according to Stage A of Example 1 and then treated according to the procedures described in Stage C of Example 2 and Stage B of Example 21, starting with the compound of Preparation P.
• the expected product is obtained according to Stages A and B of Example 21, starting with the compound obtained in Preparation Q.
• the expected product is obtained according to the process described for Example 30, starting with the compound of Example 35.
• the expected product is obtained according to Stages A and B of Example 21, starting with the compound obtained in Preparation R.
• the expected product is obtained according to the process described for Example 30, starting with the compound of Example 37.
• SB 200,646 showed a modest affinity for the 5-HT 2C receptors of the order of 200 nM and had only a weak affinity for the 5-HT 2A sites. Its selectivity is thus 6 for the 5-HT 2C sites.
• MDL 100,907 showed a very considerable selectivity of the order of 200 for the 5-HT 2A receptors, for which it has a very strong affinity.
• the compounds of the invention have a greater affinity for the 5-HT 2C receptors than the reference compound SB 200,646. Furthermore, they have a better selectivity for the 5-HT 2C receptors with respect to the 5-HT 2A receptors.
• Examples 19 and 20 which are 9 and 14 times more powerful antagonists respectively than the reference compound SB 200,646, and the compounds of Examples 6 and 7, which have a selectivity which is twice that of the reference compound SB 200,646.
• Each value represents the average of two to four determinations.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Addiction (AREA)
• Anesthesiology (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=9465049

Family Applications (2)

Family Applications After (1)

Country Status (16)

Cited By (10)

Families Citing this family (3)

Citations (1)

Family Cites Families (6)

• 1994
  • 1994-07-06 FR FR9408328A patent/FR2722194B1/fr not_active Expired - Fee Related
• 1995
  • 1995-07-04 AU AU24826/95A patent/AU684165B2/en not_active Ceased
  • 1995-07-04 CA CA002153195A patent/CA2153195C/fr not_active Expired - Fee Related
  • 1995-07-05 CN CN95109942A patent/CN1049660C/zh not_active Expired - Fee Related
  • 1995-07-05 NZ NZ272501A patent/NZ272501A/en not_active IP Right Cessation
  • 1995-07-05 DE DE69509308T patent/DE69509308T2/de not_active Expired - Lifetime
  • 1995-07-05 DK DK95401607T patent/DK0691342T3/da active
  • 1995-07-05 AT AT95401607T patent/ATE179421T1/de active
  • 1995-07-05 EP EP95401607A patent/EP0691342B1/fr not_active Expired - Lifetime
  • 1995-07-05 FI FI953308A patent/FI111945B/fi not_active IP Right Cessation
  • 1995-07-05 ES ES95401607T patent/ES2133686T3/es not_active Expired - Lifetime
  • 1995-07-05 US US08/498,217 patent/US5663191A/en not_active Expired - Lifetime
  • 1995-07-05 NO NO19952660A patent/NO311085B1/no not_active IP Right Cessation
  • 1995-07-06 JP JP7170635A patent/JP2999139B2/ja not_active Expired - Fee Related
  • 1995-07-06 ZA ZA955631A patent/ZA955631B/xx unknown
• 1997
  • 1997-01-21 US US08/786,504 patent/US5723484A/en not_active Expired - Lifetime
• 1999
  • 1999-05-07 GR GR990401249T patent/GR3030168T3/el unknown

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events